Rational Design of Bioactive, Modularly Assembled Aminoglycosides Targeting the RNA That Causes Myotonic Dystrophy Type 1

ACS Chemical Biology - United States
doi 10.1021/cb3001606
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Chemical Society (ACS)

Related search

Design of a Bioactive Small Molecule That Targets the Myotonic Dystrophy Type 1 RNA via an RNA Motif–Ligand Database and Chemical Similarity Searching

Journal of the American Chemical Society
BiochemistryColloidCatalysisChemistrySurface Chemistry
2012English

Myotonic Dystrophy Type 1

CMAJ
Medicine
2016English

Development of Pharmacophore Models for Small Molecules Targeting RNA: Application to the RNA Repeat Expansion in Myotonic Dystrophy Type 1

Bioorganic and Medicinal Chemistry Letters
Organic ChemistryMolecular MedicineMolecular BiologyBiochemistryClinical BiochemistryPharmaceutical ScienceDrug Discovery
2016English

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-Specific RNA Endonucleases That Target (CUG)n Repeats

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Disease Burden of Myotonic Dystrophy Type 1

Journal of Neurology
Neurology
2019English

Dropped Head Presentation in Myotonic Dystrophy Type 1

Neurology India
Neurology
2005English

Nuclear Envelope Transmembrane Proteins in Myotonic Dystrophy Type 1

Frontiers in Physiology
Physiology
2018English

Laboratory Abnormalities in Ambulatory Patients With Myotonic Dystrophy Type 1

Archives of Neurology
2006English

Consensus-Based Care Recommendations for Adults With Myotonic Dystrophy Type 1

Neurology: Clinical Practice
Neurology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy